CARB-X funds potential antibiotic against CRE superbugs
In a first for a Japanese company, CARB-X, a public-private collaboration that supports companies to combat antimicrobial resistance, has awarded Shionogi, of Osaka, $4.7 million to support the development of a novel beta-lactam antibiotic with potent activity against the worrisome superbugs that produce carbapenemase, including BL/BLI-resistant carbapenem-resistant Enterobacteriaceae (CRE), CARB-X said in a news release today.